This study aimed to investigate the micro ribonucleic acid-138 (miR-138) expression in oral herpes simplex (HS) and its effect on the expression of herpes simplex virus type 1 (HSV-1) lytic gene trans-acting factor infected cell protein 0 (ICP0). Forty-five rat models with oral HS were successfully established (the observation group) and another 40 healthy rats were selected as the control group. The miR-138 expression in serum of rats in the two groups were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). 293T cells infected by HSV-1 were divided into Group A and Group B after 10 days of culture. Group A was transfected by miR-138 mimics and Group B was transfected by miR-138 complementary oligonucleotide inhibitor. The expression levels of miR-138 and ICP0 messenger RNA (mRNA) in the cells of the two groups were detected by RT-PCR, and the expression levels of ICP0 protein were detected by enzyme-linked immunosorbent assay (ELISA). A total of 85 rat models with oral HS were established in this study, but only 45 models were established successfully with a success rate of 56.25%. The expression level of miR-138 in the rat serum in the observation group was higher than that in the control group (P<0.05). In addition, the expression level of ICP0 mRNA in Group A was lower than that in Group B (P<0.05). Moreover, the expression level of ICP0 protein in Group A was lower than that in Group B (P<0.05). Finally, the expression level of miR-138 in HSV was increased, suggesting that the expression of miR-138 may inhibit the expression of ICP0, thus preventing the duplication of HSV-1. Therefore, the expression of miR-138 may be used as a potential therapeutic target for HSV.
Keywords: HSV-1; ICP0; miR-138; rat models.